Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytomX TherapeuticsCTMX -5.10%38 Cash-to-Debt is 57.90 as of Jun. 2026, which is 352% above its 10-year median of 12.80. GuruFocus rates CTMX with a GF Score™ of 38/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,397 Biotechnology companies, CytomX Therapeutics ranks better than 72.58% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CytomX Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 57.90.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CytomX Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for CytomX Therapeutics's Cash-to-Debt or its related term are showing as below:
CTMX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 9.18 Med: 12.8 Max: No Debt
Current: 57.9
During the past 13 years, CytomX Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 9.18. And the median was 12.80.
CTMX's Cash-to-Debt is ranked better than 72.58% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs CTMX: 57.90
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
CytomX Therapeutics Cash-to-Debt Related Terms
CytomX Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, CytomX Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytomX Therapeutics (CTMX) has a Cash-to-Debt of 57.90 as of Jun. 2026. This is 352% above median its historical median of 12.80. Over the past decade, CytomX Therapeutics' Cash-to-Debt has ranged from 9.18 to 10,000.00. According to the industry distribution chart, CytomX Therapeutics ranks #383 out of 1397 companies in the Biotechnology industry, placing it in the top 27.4%.
Is CytomX Therapeutics' Cash-to-Debt too high?
CytomX Therapeutics' current Cash-to-Debt of 57.90 is 352% above median its 10-year median of 12.80. Over the past 10 years, this metric has ranged from a low of 9.18 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. CytomX Therapeutics' value of 57.90 is 754% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #383 out of 1397 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CytomX Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Cash-to-Debt compare to GYRE and BBOT?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #383 out of 1397 companies for Cash-to-Debt. This puts CytomX Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.78. CytomX Therapeutics' value of 57.90 is 754% above this benchmark. Historically, CytomX Therapeutics' own Cash-to-Debt has ranged from 9.18 to 10,000.00 over the past decade. While the company's 10-year median is 12.80 vs. the industry median of 6.78, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Cash-to-Debt of 57.90 is 754% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Cash-to-Debt is 57.90, which is 352% above median its own 10-year median of 12.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $3.35 — trading 2292.9% above its estimated fair value. The current Cash-to-Debt is 57.90, which is 352% above median its 10-year median of 12.80 and 754% above the Biotechnology industry median of 6.78. CytomX Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Cash-to-Debt is 57.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.35 is trading 2292.9% above its estimated GF Value™ of $0.14.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Cash-to-Debt: 57.90 (352% above median its 10-year median of 12.80)
GF Value™: $0.14 vs. price of $3.35 (2292.9% above fair value)
Industry Position: 754% above the Biotechnology median (#383 of 1397)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
38GF Score
Get the complete analysis for CTMX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
